Business
Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG") to establish an entity named...
About this update from Izotropic Corp.
[{"type":"text","content":"Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG") to establish an entity named Izotropic Africa (the "Entity") based in Casablanca, Morocco. The Entity is intended to license, market, distribute, and evaluate manufacturing and/or assembly of IzoView Breast CT and certain follow-on products in all of Africa and the Gulf Cooperation Council ("GCC"): Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (the "Business Purpose").","length":935,"tagName":"p"},{"type":"text","content":"The establishment of Izotropic Africa is intended to expand the Company's commercial footprint into regions where access to advanced breast imaging remains limited, positioning Morocco as a strategic gateway for deployment, regulatory engagement, and potential future regional manufacturing initiatives. Breast cancer is the most prevalent cancer among African women, with over 200,000 annual cases and mortality rates exceeding 50% due to delayed diagnoses and limited access to advanced care. The addressable market for advanced imaging and oncology devices in Africa is projected to exceed USD $500 million by 2030, reflecting significant unmet demand and long-term regional growth potential.","length":699,"tagName":"p"},{"type":"text","content":"Under the terms of the Agreement, the parties will incorporate the Entity and establish a local office for operations, with BG holding a 60% fully diluted interest and Izotropic holding a 40% fully diluted interest, subject to final corporate, tax, regulatory, repatriation structuring and legal advice acceptable to both Parties, and have agreed to negotiate in good faith to finalize and enter into a Formal Agreement (the "Formal Agreement") by April 30, 2026, which will define the detailed material terms and commitments contemplated in the Agreement. The Agreement will terminate upon execution of the Formal...